Cargando…
A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use
BACKGROUND: Glycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy for moderate to severe chronic obstructive pulmonary disease (COPD). Efficacy and safety trial data have found rare cases of significant QT prolongation. To our knowledge, we describe the fir...
Autores principales: | Chiu, Michael H., Al-Majed, Nawaf S., Stubbins, Ryan, Pollmann, Dylan, Sandhu, Roopinder K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908703/ https://www.ncbi.nlm.nih.gov/pubmed/27301406 http://dx.doi.org/10.1186/s13104-016-2105-4 |
Ejemplares similares
-
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
por: Singh, Dave, et al.
Publicado: (2017) -
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019) -
Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013) -
A novel model-based approach for dose determination of glycopyrronium bromide in COPD
por: Arievich, Helen, et al.
Publicado: (2012) -
Effectiveness of glycopyrronium bromide in the treatment of small
airway dysfunction: A retrospective study
por: Petrone, Albino, et al.
Publicado: (2022)